drugset / Trial / NCT01167868

A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects

NCT01167868

Phase 1 Completed 56 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindBasic science

Summary

This is a single and multiple ascending dose study in healthy male and female (of non-child bearing potential) Japanese and White volunteers, to assess the safety, tolerability, and blood and urine drug levels of FosD. FosD is being developed for the treatment of rheumatoid arthritis.

Timeline

Start
2010-07
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Fostamatinib Small molecule 50 mg Oral
Subject Fostamatinib Small molecule 200 mg Oral

Indications

No indication recorded.